Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

severe hypertriglyceridemia

- PMLiVE

AZ unveils phase 3 Brilinta data in CAD and type 2 diabetes

Reduces CV events but falls down on increased bleeding risk

- PMLiVE

AZ’s Farxiga heart failure results wow the ESC

Chases after market leader Jardiance

AstraZeneca AZ

Second TULIP trial resurrects AZ’s lupus drug anifrolumab

Will now decide whether to file treatment for approval

- PMLiVE

‘Therapeutic overcrowding’ could hit big pharma returns

Jefferies analysts identify most at-risk companies

AstraZeneca AZ

AZ builds case for its COPD triple as it chases GSK’s Trelegy

Awaiting approvals in Europe and the US

- PMLiVE

Finch Therapeutics bags $53m for microbiome therapies

In race to be first-to-market in C diff

- PMLiVE

BeiGene gets speedy US review for lymphoma drug zanubrutinib

First US filing is major milestone for Chinese firm

AstraZeneca AZ

AstraZeneca buys FDA priority review voucher from Sobi

Picks up coveted voucher for $95m

- PMLiVE

Leo Pharma to market AstraZeneca’s brodalumab outside Europe

Extends reach of the drug

Novartis day

Senators attack Novartis over ‘unconscionable’ handling of Zolgensma data

Ask FDA to hold the company ‘accountable’

- PMLiVE

Tagrisso tops rival drugs on survival in first-line lung cancer

Takes fight to Pfizer's Vizimpro

- PMLiVE

ICER closely monitoring FDA’s Zolgensma investigation

Could affect initial cost assessment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links